IDXX IDEXX Laboratories, Inc.
USHealthcareAs of 2026-07-10 16:00
Why IDXX matters now
IDEXX Laboratories, Inc. (IDXX) is a US stock in Healthcare. The latest InvestLog snapshot shows $563.57 with +0.89% on the session and $44.46B in market capitalization; recent performance reads 1-month +2.85% and YTD -16.92%.
The latest financial table shown here is Q1 2026, with revenue of $1.14B, net income of $278.4M, and EPS of $3.45. Investors can compare that operating picture with valuation signals such as P/E 42.31 and FCF yield 2.4%.
The latest indexable market news headline is "ALC vs. IDXX: Which Stock Is the Better Value Option?" from Zacks Investment Research.
Additional event context on this page matters because analyst consensus is Hold with a median target of $775.00; recent insider activity includes FENNELL GEORGE filing M-Exempt; recent congressional disclosure data includes Ro Khanna Purchase. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
42.31
PEG
2.19
P/B
28.93
P/S
9.97
EV/EBITDA
29.03
DCF Value
$179.45
FCF Yield
2.4%
Div Yield
0.0%
Margins & Returns
Gross Margin
62.1%
Operating Margin
31.6%
Net Margin
24.6%
ROE
70.9%
ROA
32.4%
ROIC
40.3%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $1.14B | $278.4M | $3.45 |
| Q4 2025 | $1.09B | $248.2M | $3.08 |
| FY 2025 | $4.30B | $1.06B | $13.08 |
| Q3 2025 | $1.11B | $274.6M | $3.40 |
Analyst Ratings
Consensus
Hold
Target (Consensus)
$747.50
Target (Median)
$775.00
Target Range
$640.00 - $800.00
Trading Activity
Insider Trades
Congress Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Medical - Diagnostics & Research
Country
US
Exchange
—
Beta
1.54
IDEXX Laboratories, Inc. is a global enterprise focused on creating, producing, and distributing a wide array of products and services. Its primary client base includes companion animal veterinary practices, the livestock and poultry industries, dairy operations, and water quality testing sectors. The company organizes its operations across several key divisions: the Companion Animal Group (CAG), Water Quality Products, Livestock, Poultry, and Dairy (LPD), and additional segments. For companion animals, IDEXX offers a comprehensive suite of point-of-care veterinary diagnostic tools, such as instruments, consumables, and rapid assay kits. It also provides reference laboratory diagnostic and consultation services, alongside practice management and diagnostic imaging solutions for veterinarians. Furthermore, the company supports the biomedical research community with health monitoring, biological materials testing, and laboratory animal diagnostic instruments and services. In the livestock, poultry, and dairy markets, IDEXX supplies diagnostic and health-monitoring solutions. Its water testing portfolio includes products designed to detect various microbiological contaminants, notably the Colilert, Colilert-18, and Colisure tests for total coliforms and E. coli, as well as Enterolert, Pseudalert, Filta-Max, Filta-Max xpress, Legiolert, and Quanti-Tray products. Beyond these, IDEXX extends its reach to human point-of-care medical diagnostics, offering electrolyte and blood gas analyzers, and SARS-CoV-2 RT-PCR tests. Other key offerings encompass in-clinic chemistry, blood and urine chemistry, hematology, and SediVue Dx analyzers, as well as SNAP rapid assay test kits. Veterinary software and services for both independent clinics and large corporate veterinary groups are also part of its offerings. The company distributes its extensive product and service catalog through its own dedicated marketing, customer service, sales, and technical service teams, supplemented by independent distributors and other resellers. IDEXX Laboratories, Inc. was established in 1983 and maintains its headquarters in Westbrook, Maine.